{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14"],"submitter":["Grotzinger KM"],"funding":["GlaxoSmithKline (GB)"],"pubmed_abstract":["<h4>Background</h4>Despite changes in the treatment paradigm towards non-interferon-based therapies, interferon-based treatments are still used in some geographical regions for treating patients with hepatitis C virus (HCV) infection. Use of eltrombopag with interferon-based treatment for patients with thrombocytopenia and HCV was assessed in two similarly designed phase 3 trials (Eltrombopag to Initiate and Maintain Interferon Antiviral Treatment to Benefit Subjects With Hepatitis C-Related Liver Disease [ENABLE-1 and ENABLE-2]). These trials also aimed to determine whether response to antiviral therapy (e.g., sustained virologic response [SVR]) is associated with changes in health-related quality of life (HRQoL). This pooled, post-hoc analysis aimed to (1) determine whether or not specif"],"journal":["Health and quality of life outcomes"],"pagination":["49"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4802726"],"repository":["biostudies-literature"],"pubmed_title":["Health-related quality of life in thrombocytopenic patients with chronic hepatitis C with or without cirrhosis in the ENABLE-1 and ENABLE-2 studies."],"pmcid":["PMC4802726"],"pubmed_authors":["Grotzinger KM","Younossi ZM","Rendas-Baum R","Theodore D","Chen PJ","Giannini EG"],"additional_accession":[]},"is_claimable":false,"name":"Health-related quality of life in thrombocytopenic patients with chronic hepatitis C with or without cirrhosis in the ENABLE-1 and ENABLE-2 studies.","description":"<h4>Background</h4>Despite changes in the treatment paradigm towards non-interferon-based therapies, interferon-based treatments are still used in some geographical regions for treating patients with hepatitis C virus (HCV) infection. Use of eltrombopag with interferon-based treatment for patients with thrombocytopenia and HCV was assessed in two similarly designed phase 3 trials (Eltrombopag to Initiate and Maintain Interferon Antiviral Treatment to Benefit Subjects With Hepatitis C-Related Liver Disease [ENABLE-1 and ENABLE-2]). These trials also aimed to determine whether response to antiviral therapy (e.g., sustained virologic response [SVR]) is associated with changes in health-related quality of life (HRQoL). This pooled, post-hoc analysis aimed to (1) determine whether or not specif","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Mar","modification":"2026-06-12T05:30:44.233Z","creation":"2019-03-27T03:10:03Z"},"accession":"S-EPMC4802726","cross_references":{"pubmed":["27004952"],"doi":["10.1186/s12955-016-0447-1"]}}